What a 🔥 International Cardio-Oncology Society Radcliffe Cardiology webinar this AM on #cardioonc QIs at Ctrs of Excellence!
Check out:
*5FU CTX tx protocols Franciscan Health
*E-consults Hartford HealthCare
*AI to🔍CTX on echo Carrie Lenneman
*Carcinoid ❤️dz screening GAGAN SAHNI
shorturl.at/NYVWC
👏1/

Does neighborhood walkability have an effect on your CV health? Read about this topic in #JACCCardioOnc JACC Journals 🫀🚶tinyurl.com/492hzr4n

✍️Khurram Nasir Jenny C. Chang Sadeer Al-Kindi, MD Anoop Titus MD Tarang Parekh, PhD, MBBS Rakesh Gullapelli Zulqarnain Javed

The #AI revolution has reached #CardioOnc ! In this #JACCCardioOnc study, an AI-ECG algorithm has been shown to accurately predict the risk of #AFib in patients with newly diagnosed #CLL . bit.ly/4bFnD9m

#ArtificialIntelligence #leusm #ECG

🌿🔬 Exciting opportunity for a post-doctoral scientist to join our team at the Center for Health and Nature in Houston! Apply now to conduct cutting-edge research at the intersection of #environment , #health , and #technology .

Very relevant read for risk prediction in #cardiooncology This is a good explainer why baseline biomarkers have minimal use in predicting cardiotoxicity

🎉Congrats to Vivek Narayan for his exciting work in #CardioOnc exploring coronary microvascular dysfunction in men with #prostate cancer published in the Journal of Clinical GU Cancer! A great team effort Marie Guerraty MD, PhD Ravi B. Parikh Biniyam Gemechu

📰tinyurl.com/3kbk2tun

There is a lot of movement in prostate cancer screening research and practice these days, as this week’s JAMA illustrates:
🔵 15-year update to CAP trial
🔵 Preliminary communication from ProScreen
🔵 Insightful editorial by Jeff Tosoian, MD, MPH and colleagues

1/n

Recently, Dr. Arjun Ghosh, a member of our British Chapter, traveled to Mumbai to discuss the future of cardio-oncology with members and trainees at Tata Memorial Hospital.

Read More About the Trip Here: tinyurl.com/DrGhoshVisit

#AUA24 Yaw Nyame State-of-the-Art Lecture: Prostate Cancer Screening High-risk Groups

New Prostate Cancer Foundation Screening Guidelines for Black Men in 🇺🇸

Guideline statements 👇 NEJM Evidence UroToday.com

Exercise may be the single most potent medical intervention ever known. Its benefits in prevention outstrip any known drugs: 50% reduction in the risk of cardiovascular disease, 50% reduction in the risk of many cancers, positive effects on mental health, pulmonary health, GI

Combined #ICI and #VEGFI treatment regimens & trials are on the rise📈Are #CV eligibility criteria and #AE reporting keeping up? JACC Journals #JACCCardioOnc

🧐tinyurl.com/yjwby5uf

GCOS will be here before you know it!

Join us September 22 - 24th for the premier global gathering of cardio-oncologists. Save your spot: gcos2024.com/registration #cardioonc #cardiology #hematology #oncology #hearthealth

Excellent discussion to show relevance of #cardioonc in #prostatecancer at Advanced Prostate Cancer Consensus Conference papers to see from our world to answer some of these questions
- jacc.org/doi/10.1016/j.… Tanya Dorff June Rhee
-sciencedirect.com/science/articl… Renato D Lopes Celestia (Tia) S. Higano, MD, FACP Darryl Leong
-

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Majority of the panelist recommend break in systemic therapy in mHSPC #prostatecancer after deep PSA response👇if there is Rx break, most recommend suspending all treatment (both ADT and ARPI) OncoAlert PCF Science UroToday.com silke gillessen

Avirup Guha, MBBS, MPH, FICOS, FACC, FAHA Georgia Cancer Center Martha K. Terris MD MCG Urology Priyanshu nain Harikrishnan Hyma Raman Omar Elsayed, MD MPH (Omar Makram) Jorge Cortes MD And that's why we appreciate you! 🙏🤣

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 increasing recognition among panelists about cardiovascular issues in #ProstateCancer pts👉many ordering baseline EKGs & ECHO before starting ADT+/-ARPI👇Courtney Bugler ‘s great question on holistic care of pts OncoAlert UroToday.com silke gillessen

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 Pierre Blanchard, MD ‘s excellent talk on serum testosterone suppression after limited ADT and testosterone recovery 👉implications on QOL, & testosterone replacement Rx👇OncoAlert Oncology Brothers UroToday.com PCF Science Courtney Bugler

That’s what we do at Georgia Cancer Center Martha K. Terris MD MCG Urology Zach Klaassen Priyanshu nain Harikrishnan Hyma Raman Omar Elsayed, MD MPH (Omar Makram) Jorge Cortes MD

Interesting take. I do not believe the data to be compelling enough for medication choice for GnRH agonist vs antagonist. However data is compelling enough for event rates in patients co managed by cardio-onc and med-onc vs med-onc only. As long as your patient lives beyond 60

Do you remember when you joined X? I do! #MyXAnniversary